Skip to main content
padlock icon - secure page this page is secure

Open Access The devil we know: is the use of injectable agents for the treatment of MDR-TB justified?

Download Article:
(PDF 238.8 kb)
For decades, second-line injectable agents (IAs) have been the cornerstone of treatment for multidrug-resistant tuberculosis (MDR-TB). Although evidence on the efficacy of IAs is limited, there is an expanding body of evidence on the serious adverse events caused by these drugs. Here, we present the results of a structured literature review of the safety and efficacy of IAs. We review the continued widespread use of these agents in the context of therapeutic alternatives—most notably the newer TB drugs, bedaquiline and delamanid—and from the context of human rights, ethics and patient-centered care. We conclude that there is limited evidence of the efficacy of IAs, clear evidence of the risks of these drugs, and that persons living with MDR-TB should be informed about these risks and provided with access to alternative therapeutic options.
No Reference information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Keywords: MDR-TB; drug-resistant TB; hearing loss; injectable agents; ototoxicity

Document Type: Research Article

Affiliations: 1: Médecins Sans Frontières, Khayeltisha 2: TB Proof, Cape Town 3: Division of Medical Microbiology, University of Cape Town, Cape Town, South Africa 4: Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa 5: Stop TB Partnership, Geneva, Switzerland 6: Desmond Tutu TB Center, Stellenbosch University, Cape Town, South Africa 7: Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts 8: HIV/TB Project, Treatment Action Group, New York, New York 9: Beth Israel-Deaconess Medical Center, Boston, Massachusetts, USA 10: Centre for International Health, Imperial College, London, UK 11: College of Liberal Arts and Sciences, Wayne State University, Detroit, Michigan, USA 12: TB Proof, Cape Town, Division of Medical Microbiology, University of Cape Town, Cape Town, South Africa

Publication date: November 1, 2017

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on lung health world-wide.

    To share scientific research of immediate concern as rapidly as possible, The Union is fast-tracking the publication of certain articles from the IJTLD and publishing them on The Union website, prior to their publication in the Journal. Read fast-track articles.

    Certain IJTLD articles are also selected for translation into French, Spanish, Chinese or Russian. These are available on the Union website.

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more